CollPlant Biotechnologies introduced BioFlex, a ready‑to‑print recombinant human collagen (rhCollagen) kit designed for Digital Light Processing (DLP) 3D bioprinting. The kit contains Collink.3D™ 50, a biodegradable polymer, and proprietary photoactive agents that enable high‑resolution printing of tissue models, engineered tissues, and transplantable organs.
The product positions CollPlant as a plant‑based, animal‑free alternative that offers enhanced tensile strength, elasticity, and structural integrity compared with conventional bioinks. By streamlining formulation and providing clear printing guidelines, BioFlex aims to cut development time and improve reproducibility for researchers building complex, biologically relevant structures.
CollPlant’s launch expands its commercial footprint beyond its existing dermal filler partnership with AbbVie and its regenerative breast implant program. The move signals the company’s intent to monetize its rhCollagen platform across multiple markets, potentially opening new revenue streams and reducing reliance on milestone payments from external partners.
CEO Yehiel Tal said, "BioFlex, our ready‑to‑use rhCollagen‑based bioink kit, significantly streamlines the formulation process while preserving design flexibility." The statement underscores the kit’s ease of use and adaptability for a wide range of bioprinting applications.
CollPlant’s core technology is plant‑based recombinant human collagen identical to human collagen, a feature that has attracted collaborations with AbbVie for dermal and soft‑tissue fillers and with Stratasys for 3D‑printed tissues and scaffolds. The company has faced financial challenges, reporting significant net losses in recent years and a substantial revenue decline in 2024 compared with 2023, largely due to the absence of a large milestone payment from AbbVie in 2024. Capital raises have been undertaken to support ongoing development.
The BioFlex launch represents a strategic pivot toward diversifying revenue streams and reducing dependence on external milestone payments. It also aligns with CollPlant’s broader pipeline, which includes regenerative breast implants and photocurable dermal fillers targeting the medical aesthetics and regenerative medicine markets.
The product launch is a major operational milestone that could reshape CollPlant’s business model, offering a new avenue for growth while addressing unmet needs in the 3D bioprinting market for researchers and industry.
The announcement reflects CollPlant’s continued focus on innovation and market expansion, positioning the company to capture a share of the growing bioprinting and regenerative medicine sectors.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.